Nabilone

Cannabinoid — ALIMENTARY TRACT AND METABOLISM

Key facts

Nabilone is an ofm drug in the Cannabinoid class catalogued in DrugCentral. It was first approved by the FDA in 1985. DrugCentral lists 4 molecular targets, including Cnr2, Cnr1 and CNR1. Recorded indications include Chemotherapy-induced nausea and vomiting.

• Approval status: ofm (first approved 1985 by the FDA).
• Drug class: Cannabinoid.
• Molecular targets: Cnr2, Cnr1, CNR1 and CNR2 (4 listed in DrugCentral).
• Indications: Chemotherapy-induced nausea and vomiting.
• ATC code: A04AD11 (Other antiemetics).
• Molecular formula: C24H36O3; molecular weight 372.55 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Chemotherapy-induced nausea and vomiting

Contraindications (12)

• Breastfeeding (mother)
• Chronic heart failure
• Conduction disorder of the heart
• Depressive disorder
• Disorder of coronary artery
• Hepatic failure
• Hypertensive disorder
• Low blood pressure
• Mania
• Psychotic disorder
• Schizophrenia
• Substance abuse

Mechanism & targets

• Established pharmacologic class: Cannabinoid

Molecular targets (4)

Target	Gene	Action	Activity
Cannabinoid receptor 2	Cnr2	unknown	Ki 8.74
Cannabinoid receptor 1	Cnr1	unknown	Ki 8.66
Cannabinoid receptor 1	CNR1	agonist	Ki 8.40
Cannabinoid receptor 2	CNR2	unknown	Ki 8.20

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1985-12-26	FDA	—	MEDA PHARMS

ATC classification

ATC code	Therapeutic hierarchy
A04AD11	ALIMENTARY TRACT AND METABOLISM › ANTIEMETICS AND ANTINAUSEANTS › ANTIEMETICS AND ANTINAUSEANTS › Other antiemetics

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Inspiratory capacity decreased	485.8
White blood cell count abnormal	368.5
Somatic symptom disorder	179.8
Musculoskeletal stiffness	173.8
Sacroiliitis	163.4
Terminal insomnia	149.4
Pelvic pain	124.8
Pain	123.2
Rheumatoid arthritis	114.7
Gait disturbance	108.8
Mood altered	104.4
Cardiac disorder	75.8

Chemical structure

• Molecular formula: C₂₄H₃₆O₃
• Molecular weight: 372.55 g/mol
• CAS number: —
• InChIKey: GECBBEABIDMGGL-UHFFFAOYSA-N
• PubChem CID: 5284592

CCCCCCC(C)(C)C1=CC(O)=C2C3CC(=O)CCC3C(C)(C)OC2=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Nabilone used for?

DrugCentral lists the following indications for Nabilone: Chemotherapy-induced nausea and vomiting.

How does Nabilone work?

Its molecular targets in DrugCentral include Cnr2, Cnr1, CNR1 (agonist) and CNR2.

When was Nabilone first approved?

Nabilone was first approved by the FDA in 1985.

What drug class does Nabilone belong to?

Nabilone is in the Cannabinoid class.

What is the chemical formula of Nabilone?

Nabilone has the molecular formula C24H36O3 and a molecular weight of 372.55 g/mol.

Sources

• DrugCentral drug card 1862 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2218896 — compound record and bioactivity
• PubChem CID 5284592 — chemical identifiers
• DrugBank DB00486 — drug record
• FDA UNII 2N4O9L084N — substance identity
• DailyMed: FDA labels for Nabilone — current prescribing information (label search)
• UniProt P21554 (CNR1) — target protein
• UniProt P34972 (CNR2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.